Search results
Results From The WOW.Com Content Network
In March 2016, obiltoxaximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax. [10]In September 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for ...
If infection occurs, treatment is with antibiotics and possibly antitoxin. [6] The type and number of antibiotics used depend on the type of infection. [5] Antitoxin is recommended for those with widespread infection. [5] A rare disease, human anthrax is most common in Africa and central and southern Asia. [11]
Anthracimycin is a polyketide antibiotic discovered in 2013. Anthracimycin is derived from marine actinobacteria . In preliminary laboratory research, it has shown activity against Bacillus anthracis , [ 1 ] the bacteria that causes anthrax , and against methicillin-resistant Staphylococcus aureus (MRSA).
Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. [3] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.
Raxibacumab [2] is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax.Its efficacy has been proven in rabbits and monkeys. [3] In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax ...
Anthrax immune globulin, tradename Anthrasil, is a human immune globulin that is used in combination with antibiotics to treat anthrax. [2] It was developed by Cangene and purchased in 2011 by the Biomedical Advanced Research and Development Authority (BARDA) under Project Bioshield.
For premium support please call: 800-290-4726 more ways to reach us
Shortly afterward, it was recommended that doxycycline was a more appropriate drug to treat anthrax exposure. [173] A widened use of the broad-spectrum antibiotic ciprofloxacin had also raised serious concerns amongst scientists about the creation and increased spread of drug-resistant bacteria strains. [173]